| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
5 Steroidogenic Pathway
Department of Pediatrics and Metabolic Research Unit (C.E.F., W.L.M.), University of California, San Francisco, California 94143-0978; and Division of Endocrinology and Metabolism, Department of Internal Medicine (R.J.A.), University of Texas Southwestern Medical Center, Dallas, Texas 75390-8857
Address all correspondence and requests for reprints to: Richard J. Auchus, M.D., Ph.D., Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8857. E-mail: richard.auchus{at}utsouthwestern.edu.
| Abstract |
|---|
|
|
|---|
-hydroxylation and 17,20-lyase conversion of 21-carbon steroids to 19-carbon precursors of sex steroids. P450c17 can mediate testosterone biosynthesis via the conversion of pregnenolone to dehydroepiandrosterone (the
5 pathway) or via conversion of progesterone to androstenedione (the
4 pathway). In many species, the 17, 20-lyase activity of P450c17 for one pathway dominates, reflecting the preferred steroidogenic pathway of that species. All studies of recombinant human P450c17 and of human adrenal microsomes have found high 17, 20-lyase activity only in the
5 pathway. Because the 17, 20-lyase activities in both the
4 and
5 pathways for testicular P450c17 have not been directly compared, however, it is not known if the
5 pathway dominates in the human testis. To resolve this issue, we assayed the conversion of 17
-hydroxypregnenolone to dehydroepiandrosterone (
5 17, 20-lyase activity) and of 17
-hydroxyprogesterone to androstenedione (
4 17, 20-lyase activity) by human fetal testicular microsomes. We obtained apparent Michaelis constant (Km) and maximum velocity (Vmax) values of 1.0 µM and 0.73 pmol·min-1·µg-1 for
5 17, 20-lyase activity and of 3.5 µM and 0.23 pmol·min-1·µg-1 for
4 17, 20-lyase activity. Catalytic efficiencies, expressed as the ratio Vmax/Km, were 0.73 and 0.066 for the
5 and
4 reactions, respectively, indicating 11-fold higher preference for the
5 pathway. We conclude that the majority of testosterone biosynthesis in the human testis proceeds through the conversion of pregnenolone to dehydroepiandrosterone via the
5 pathway. | Introduction |
|---|
|
|
|---|
-hydroxylation and the 17, 20-lyase reaction. In the human adrenal zona glomerulosa, absence of P450c17 directs steroidogenesis to aldosterone. In the zona fasciculata, the 17
-hydroxylase activity of P450c17 far exceeds its 17, 20-lyase activity, resulting in cortisol production. In the zona reticularis, 17, 20-lyase activity is abundant, resulting in the synthesis of the C19 precursors of sex steroids, principally dehydroepiandrosterone (DHEA) and its sulfate, as well as androstenedione (
4A) (1).
P450c17 may drive sex steroid production by converting pregnenolone to 17
-hydroxypregnenolone (17OHPreg) and then to DHEA along the
5 pathway. DHEA is then converted in two steps to testosterone. Alternatively, flux may simultaneously occur via the
4 pathway: progesterone to 17
-hydroxyprogesterone (17OHP) to
4A (Fig. 1
). The dominant pathway to C19 steroids varies for P450c17 from different species, due principally to discrepancies in the catalytic efficiencies for the 17, 20-lyase reactions in the
5 and
4 pathways. The catalytic activities of bovine P450c17 (2, 3) resemble those of the human enzyme, but pig (4, 5, 6, 7), frog (8), and trout (9) P450c17 have readily measured
4 17, 20-lyase activity, whereas the
4 pathway predominates with the rat (10), hamster (11, 12), and guinea pig (13, 14) enzymes. Consequently, many endocrinology texts have diagrammed both adrenal C19 steroid and testicular testosterone biosynthesis proceeding via both the
4 and
5 pathway or predominantly via the
4 pathway.
|
5 pathway. Thus, in newborns with 21-hydroxylase deficiency, serum concentrations of 17OHP are generally elevated 100-fold, but concentrations of
4A are elevated only 5- to 10-fold (15), indicating poor conversion of 17OHP to
4A by adrenal
4 17, 20-lyase activity. When human P450c17 is expressed in transfected COS-1 cells (16, 17) or in microsomes from genetically engineered yeast (18), it catalyzes the conversion of 17OHPreg to DHEA approximately 20 times more efficiently than the conversion of 17OHP to
4A. The same dominance of the
5 17, 20-lyase activity is observed when purified, modified human P450c17 is studied in reconstituted assay systems (19), and the
5 pathway also dominates in P450c17 from several other primate species (20).
The pathway leading to C19 testosterone precursors in the human testis, however, has been the subject of some controversy. Early studies using [3H]-pregnenolone and -progesterone precursors suggested that the human testis makes C19 steroids through both the
4 and the
5 pathways (21). Some data even suggested that the adrenal glands and gonads used different isozymes of P450c17 (22), but the cloning of the human adrenal and testicular P450c17 cDNAs showed that a single gene encodes the same protein in both tissues (23). Nevertheless, it is conceivable that the dominant pathways to C19 steroids might differ in the human adrenal and gonads, and that such a testicular pathway was not seen in previous studies of P450c17 in the adrenal or in vitro.
P450c17 functions as part of a catalytic system comprised of P450c17 itself, cytochrome P450 oxidoreductase, and cytochrome b5 (b5). The 17, 20-lyase activities of the P450c17 system can be dramatically modulated by at least three posttranslational events. First, a high molar ratio of the reductase to P450c17 favors 17, 20-lyase activity (7, 17). Second, b5 acts allostericly to favor 17, 20-lyase activity (18, 24, 25), and b5 is preferentially expressed in the zona reticularis of the adrenal (26, 27, 28), which produces large amounts of C19-steroids. Finally, the 17, 20-lyase activity of P450c17 is strongly influenced by serine/threonine phosphorylation (29, 30). Thus, it is conceivable that other, as yet unidentified, posttranslational events might favor
4 17, 20-lyase activity in the Leydig cell but not occur in the adrenal or in in vitro systems. To address this question directly, we examined the 17, 20-lyase activity of P450c17 in human fetal testis microsomes.
| Materials and Methods |
|---|
|
|
|---|
Human testis tissue from a fetus 21.5 wk of gestation was obtained from the American Association of Tissue Banks (McLean, VA; aatb@aatb.org). The fetal testis tissue was disrupted with 30 strokes of a glass homogenizer on ice with 0.25 ml of 0.25 M sucrose/5 mM EDTA/10 mM Tris·HCl, pH 7.4. Crude cellular debris was removed, and a premicrosomal pellet was obtained after centrifugation at 10,000 x g for 10 min. The supernatant was centrifuged at 100,000 x g for 45 min, and the pellet, containing enriched microsomes, was resuspended in 0.1 ml of TEG (50 mM Tris·HCl/1 mM EDTA, pH 8.0/20% (vol/vol) glycerol). The microsome preparation was kept frozen at -70 C until needed. Microsomal protein concentration was determined colorimetrically (Protein Assay Dye Reagent, Bio-Rad, Hercules, CA) using BSA as a standard. Microsomal P450 content was estimated from type I difference spectra with progesterone, recorded on a Shimadzu UV-160U spectrophotometer as described (20).
P450c17 enzyme assays
Enzyme kinetic studies were performed using a constant amount of microsomal protein (2.3 µg for testing the
5 pathway, 9.2 µg for testing the
4 pathway) and four different substrate concentrations. Fetal testis microsomes were preincubated in 50 mM potassium phosphate buffer (pH 7.4) with 0.54.0 µM steroids (added in 4 µl of ethanol) in a total volume of 200 µl at 37 C for 2 min. Each reaction also contained either 100,000 cpm of [3H]-17OHPreg (21.2 Ci/mmol) or 40,000 cpm of [3H]-17OHP (66 Ci/mmol) (Perkin-Elmer Life Sciences, Boston, MA). To start the reaction, 1 mM reduced nicotinamide-adenine dinucleotide phosphate (Sigma, St. Louis, MO) was added, and the reaction was returned to 37 C for 50 min (17OHPreg) or 60 min (17OHP). Steroids were extracted from the reaction mixture with 400 µl of ethyl acetate/isooctane (1:1), concentrated by evaporation under continuous nitrogen flow, and separated by thin-layer chromatography on phosPE SIL G/UV silica gel plates (Whatman, Maidstone, Kent, UK) using 3:1 chloroform/ethyl acetate as the solvent system (18). Incubations with [14C]-progesterone or -pregnenolone at 1 µM steroid, which approximates intratesticular concentrations of many steroids (31), were conducted in 100 µl of phosphate buffer as described above for the 17-hydroxysteroids at 37 C for 60 min with 2.3 µg microsomal protein. The radiolabeled steroids were quantified by phosphorimaging analysis on a Storm 860 PhosphorImager using ImageQuant software version 1.2 for Macintosh (Molecular Dynamics, Sunnyvale, CA).
Data analysis
All assays were performed three times, with each data point in duplicate or triplicate, and data are presented as means ± SEM. Kinetic behavior was approximated as a Michaelis-Menten system, and data are plotted as described by Lineweaver and Burk and by Dixon and Webb (32). Curve fitting for calculation of maximum velocity (Vmax) and apparent Michaelis constant (Km) values was performed with PRISM 3.02 (GraphPad Software, Inc., San Diego, CA).
| Results |
|---|
|
|
|---|
To determine the catalytic efficiencies of the 17, 20-lyase reactions for both the
4 and the
5 pathways in human testis microsomes, we measured the conversion of [3H]-17OHPreg to DHEA and of [3H]-17OHP to
4A. By using microsomal protein preparations and radiolabeled 17-hydroxysteroid intermediates, we directly compared the kinetics of the two 17, 20-lyase reactions, avoiding the assumptions, side reactions, and pitfalls that have led to incorrect assessments of steroid metabolism by other methods (37). Calculation of the apparent Michaelis constants (Km) and maximum velocities (Vmax) (38) for 17OHPreg and 17OHP showed a large preference for the
5 pathway (Fig. 2
). The Km for
5 17OHPreg was 1.0 µM, whereas the Km for
4 17OHP was 3.5 µM, favoring the
5 substrate by 3.5-fold. The Vmax for
5 17OHPreg was 0.73 pmol·min-1·µg-1, whereas the Vmax for
4 17OHP was 0.23 pmol·min-1·µg-1, demonstrating that the 17, 20-lyase reaction proceeded over three times faster for the
5 pathway at saturating substrate concentrations. The ratio Vmax/Km, an index of overall catalytic efficiency, was 11-fold higher for the
5 pathway than the
4 pathway (Table 1
). These data demonstrate that, by all kinetic measures, the P450c17 catalytic system of the human testis favors the
5 pathway for the 17, 20-lyase reaction.
|
|
5 pathway than for the
4 pathway, we incubated fetal testis microsomes with 1 µM [14C]-pregnenolone and -progesterone. After 60 min, comparable amounts of 17-hydroxysteroids had accumulated in both incubations, yet little
4A was produced from progesterone during this time (Fig. 3
-hydroxylase reaction followed by 17, 20-lyase reaction) is more efficient for the
5 pathway than for the
4 pathway.
|
| Discussion |
|---|
|
|
|---|
Initial studies of testosterone synthesis in human fetal testis found comparable conversion rates of pregnenolone and progesterone to testosterone (21). Other investigators found that homogenates from whole testes of adult men also converted pregnenolone rapidly through 17OHPreg to DHEA (40). The adult testis homogenates, in contrast, produced little progesterone and
4A from pregnenolone, and 17OHP accumulated slowly, suggesting poor
4 17, 20-lyase activity relative to the
5 pathway (40, 41). The enzyme sources used by these two groups are not equivalent because, unlike the fetal testis, over 90% of the mass of the adult testis is comprised of seminferous tubules (42). Furthermore, neither study performed incubations with 17-hydroxysteroid intermediates, and 17, 20-lyase activity was inferred from multistep transformations to testosterone in complex mixtures. Because pregnenolone is the first committed intermediate in sex steroid biosynthesis from cholesterol, studies starting with progesterone might overestimate testosterone production rates by omitting the 3ß-hydroxysteroid dehydrogenase-
5/4-isomerase (3ß-HSD) step. With pregnenolone as the substrate, the Km of 3ß-HSD is more than five times higher than that of P450c17 (43), suggesting that 3ß-HSD may be the rate-limiting step in the conversion of pregnenolone to testosterone in the testis. This explanation would reconcile previous studies with our data. We infer that our results also apply to adult Leydig cells, but adult testis tissue was not available for our study.
Our results demonstrate that the catalytic efficiency for the 17, 20-lyase reaction of P450c17 in human fetal testis is 11-fold higher for the
5 pathway than for the
4 pathway. This
5 preference is consistent with results obtained with human P450c17 obtained from adrenal microsomes (18) or expressed in heterologous systems (16, 18, 19). We calculate a Vmax for the conversion of 17OHPreg to DHEA in fetal testis microsomes (the
5 17, 20-lyase reaction) of more than 11 pmol·min-1·pmol P450-1, which is 410 times faster than the highest rates measured in optimized assays with recombinant enzyme (18, 19). Consequently, the rates of the 17, 20-lyase reactions in the fetal testis, even for the minor
4 pathway, are higher than in other systems, but the preference of the
5 pathway is lower (18) (Table 1
).
Thus, the 17, 20-lyase activity of the P450c17 catalytic system in the human fetal testis is relatively high in both the
5 and
4 pathways, exceeding rates measured with recombinant P450c17 in heterologous expression systems. Reasons for the rapid turnover rates might include optimal abundance of P450 oxidoreductase (7) and b5 (18, 25), favorable composition of phospholipids, low amounts of competing enzymes, and proper phosphorylation state (29, 30). Because the catalytic efficiency of the 17, 20-lyase reaction for the testicular P450c17 system favors the
5 pathway by 11-fold, the majority of testosterone biosynthesis in the human testis derives from the conversion of pregnenolone to DHEA via the
5 pathway.
| Footnotes |
|---|
Abbreviations:
4A, Androstenedione; DHEA, dehydroepiandrosterone; 3ß-HSD, 3ß-hydroxysteroid dehydrogenase-
5/4-isomerase; Km, apparent Michaelis constant; 17OHP, 17
-hydroxyprogesterone; 17OHPreg, 17
-hydroxypregnenolone; Vmax, maximum velocity.
Received January 28, 2003.
Accepted April 10, 2003.
| References |
|---|
|
|
|---|
-hydroxylase cytochrome P450 cDNA in non-steroidogenic (COS-1) cells. Science 234:12581261
-hydroxylase and C17, 20-lyase) associated with one protein. Biochemistry 20:40374042[CrossRef][Medline]
-hydroxy C21 steroids as obligatory intermediates. J Steroid Biochem 14:12491252[CrossRef][Medline]
-hydroxylase/17, 20 lyase) cDNA cloning, enzymatic properties and temporal pattern of ovarian P450c17 mRNA expression during oogenesis. FEBS Lett 301:6064[CrossRef][Medline]
from testis: characterization of a full-length cDNA encoding a unique steroid hydroxylase capable of catalyzing both
4 and
5-steroid-17, 20-lyase reactions. Mol Endocrinol 3:968975
-hydroxylase/17, 20-lyase) using site-directed mutagenesis and molecular modeling. J Steroid Biochem Mol Biol 80:99107[CrossRef][Medline]
-hydroxylase/17, 20 lyase): tissue distribution, regulation, and substrate specificity of the expressed enzyme. DNA Cell Biol 13:11991212[Medline]
Pro causes 17
-hydroxylase deficiency. J Biol Chem 266:1599215998
-hydroxylase and 17, 20 lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 132:24982506
-hydroxylase-17, 20-lyase (CYP17) by cytochrome b5: endocrinological and mechanistic implications. Biochem J 308:901908
-hydroxylase/C17, 20 lyase cytochrome P450. J Biol Chem 259:39713976
-hydroxylase/17, 20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A 84:407411
-hydroxylase/17, 20-lyase cytochrome P450 (P450c17) and NADPH-cytochrome P450 reductase (reductase) but not 3ß-hydroxysteroid dehydrogenase/
54 isomerase (3ß-HSD). J Clin Endocrinol Metab 84:33823385
-hydroxylase/17, 20 lyase) and P450c21 (21-hydroxylase) in the human fetus. J Clin Endocrinol Metab 63:11451150This article has been cited by other articles:
![]() |
R.-S. Wang, S. Yeh, C.-R. Tzeng, and C. Chang Androgen Receptor Roles in Spermatogenesis and Fertility: Lessons from Testicular Cell-Specific Androgen Receptor Knockout Mice Endocr. Rev., April 1, 2009; 30(2): 119 - 132. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Nguyen, C. J. Corbin, J. C. Pattison, I. M. Bird, and A. J. Conley The Developmental Increase in Adrenocortical 17,20-Lyase Activity (Biochemical Adrenarche) Is Driven Primarily by Increasing Cytochrome b5 in Neonatal Rhesus Macaques Endocrinology, April 1, 2009; 150(4): 1748 - 1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tiosano, C. Knopf, I. Koren, N. Levanon, M. F Hartmann, Z. Hochberg, and S. A Wudy Metabolic evidence for impaired 17{alpha}-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity Eur. J. Endocrinol., March 1, 2008; 158(3): 385 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Blystone, C. S. Lambright, K. L. Howdeshell, J. Furr, R. M. Sternberg, B. C. Butterworth, E. J. Durhan, E. A. Makynen, G. T. Ankley, V. S. Wilson, et al. Sensitivity of Fetal Rat Testicular Steroidogenesis to Maternal Prochloraz Exposure and the Underlying Mechanism of Inhibition Toxicol. Sci., June 1, 2007; 97(2): 512 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dharia, A. Slane, M. Jian, M. Conner, A. J. Conley, and C. R. Parker Jr Colocalization of P450c17 and Cytochrome b5 in Androgen-Synthesizing Tissues of the Human Biol Reprod, July 1, 2004; 71(1): 83 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Sherbet, D. Tiosano, K. M. Kwist, Z. Hochberg, and R. J. Auchus CYP17 Mutation E305G Causes Isolated 17,20-Lyase Deficiency by Selectively Altering Substrate Binding J. Biol. Chem., December 5, 2003; 278(49): 48563 - 48569. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |